You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1
Saad Alghamdi
 -- 2918 2022-07-13 14:29:44 |
2 format correct
Vivi Li
 Meta information modification 2918 2022-07-14 04:20:27 |

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Khan, F.B.;  Ansari, M.A.;  Uddin, S.;  Palakott, A.R.;  Anwar, I.;  Almatroudi, A.;  Alomary, M.N.;  Alrumaihi, F.;  Alkhayl, F.F.A.;  Alghamdi, S.; et al. Camel Milk. Encyclopedia. Available online: https://encyclopedia.pub/entry/25106 (accessed on 19 July 2025).
Khan FB,  Ansari MA,  Uddin S,  Palakott AR,  Anwar I,  Almatroudi A, et al. Camel Milk. Encyclopedia. Available at: https://encyclopedia.pub/entry/25106. Accessed July 19, 2025.
Khan, Farheen Badrealam, Mohammad Azam Ansari, Shahab Uddin, Abdul Rasheed Palakott, Irfa Anwar, Ahmad Almatroudi, Mohammad N. Alomary, Faris Alrumaihi, Faris F. Aba Alkhayl, Saad Alghamdi, et al. "Camel Milk" Encyclopedia, https://encyclopedia.pub/entry/25106 (accessed July 19, 2025).
Khan, F.B.,  Ansari, M.A.,  Uddin, S.,  Palakott, A.R.,  Anwar, I.,  Almatroudi, A.,  Alomary, M.N.,  Alrumaihi, F.,  Alkhayl, F.F.A.,  Alghamdi, S.,  Muhammad, K.,  Huang, C.,  Daddam, J.R.,  Khan, H.,  Maqsood, S., & Ayoub, M.A. (2022, July 13). Camel Milk. In Encyclopedia. https://encyclopedia.pub/entry/25106
Khan, Farheen Badrealam, et al. "Camel Milk." Encyclopedia. Web. 13 July, 2022.
Camel Milk
Edit
This entry is adapted from the peer-reviewed paper 10.3390/life12070990

Camel milk (CM) constitutes an important dietary source in the hot and arid regions of the world. CM is a colloidal mixture of nutritional components (proteins, carbohydrates, lipids, vitamins, and minerals) and non-nutritional components (hormones, growth factors, cytokines, immunoglobulins, and exosomes). 

bioactive peptides camel milk cancer diabetes molecular signaling exosomes human diseases therapeutics

1. Introduction

It is widely recognized that camel milk (CM) is a valuable nutritional source for people living in the hot and arid regions of the world. CM is a complex biological fluid that contains not only nutritional components, including macronutrients and micronutrients, but also non-nutritional components, such as hormones, growth factors, immune system products, and exosomes [1][2][3].
Evidence has shown that CM is used for therapeutic benefits against various diseases and conditions [4][5][6][7][8][9]. To this end, CM has been reported to provide therapeutic benefits against various pathophysiological conditions, including diabetes, hypertension, cancer, inflammatory and allergic responses as discussed in subsequent sections [1][7][10][11][12][13]. Amongst all these beneficial properties, its therapeutic potential against diabetes has been extensively explored. Reports have shown that CM consumption not only lowers the prevalence of diabetes, but also improves the detrimental effects of hyperglycemic condition, as well as reducing the insulin therapy required by type-1 diabetic patients [5][6][7][11][14][15][16][17][18]. The antidiabetic potentials of CM were mainly accredited to the presence of insulin and/or insulin-like peptides in CM. However, this belief has undergone a paradigm shift as a consequence of independent studies that have explicitly highlighted the fact that that these insulin/insulin-like peptides are completely hydrolyzed by gastrointestinal enzymes [19][20][21] This has prompted the researcher to study the CM protein hydrolysates and their bioactive peptides; indeed, lately, this area of research has garnered much attention all across the globe [5][22][23][24].

2. Brief Overview of Camel Milk (CM) Components

2.1. Nutritional Components (Macronutrients and Micronutrients)

Over the years, much attention has been diverted toward the consumption of CM as an alternative to milk from other sources, apparently due to its therapeutic benefits and lower allergenicity issues. Indeed, the physicochemical composition of CM differs considerably from that of milk from other domestic dairy animals. It has been argued that the physicochemical composition of CM is dependent on various factors, including geographical origin, breed, age, parity, season, ecology, feed and feeding approach, and also on the analytical measurement procedures used to measure the components [25][26]. Milk is a composite mixture of various proteins, carbohydrates, lipids, minerals, vitamins, etc., and CM is known to contain low amounts of fats, proteins, and oligosaccharides and high amounts of vitamins, minerals, and water [27][28]. Among macronutrients, according to meta-analysis and literature data, the fat composition of CM varies but is reportedly lower than that of milk from other domestic animals [26]. The fat component consists mainly of triglycerides and, importantly, very low levels of cholesterol [29][30]. Interestingly, the constituent of CM that is considered to have the greatest impact on its nutritional value and confer beneficial properties are proteins. Nevertheless, it is not entirely clear whether the beneficial effects of CM can be accredited to a particular component acting on one specific target or whether they are the result of the harmonious actions of multiple components in the system [7].
An overview of various active research endeavors related to CM proteins in food science is depicted in Figure 1. Basically, the main protein constituents of CM are casein proteins (CPs) and whey proteins (WPs). The proportion of CPs in CM is 50–80%, consisting of αS1-casein, αS2-casein, β-casein, and κ-casein, with an abundance of β-casein [31]. The abundance of β-casein in CM has been considered responsible for the distinctive and intriguing biological characteristics of CM, akin to those of human milk [32]. Furthermore, CPs of CM possess higher molecular weight than CPs of bovine milk (BM) [22][31][33]. In addition, the dimensions of casein micelles in CM are greater than those of casein micelles in BM [34]. WPs represent another important constituent, comprising approximately 30% of total CM proteins [35][36]. The major WPs in CM are α-lactalbumin (α-LA), camel serum albumin (CSA), lactoferrin (LF), and thermostable immunoglobulins (Igs) (IgG and IgM). In contrast to BM, wherein β-lactoglobulin (β-LG) represents the major WP component, the main WP component in CM is α-LA (50%), followed by CSA (35%) [22][32][37]. The levels of β-LG in CM are either very low or absent altogether. As β-LG is the main protein in BM responsible for eliciting allergic responses, the absence of β-LG in CM is likely responsible for its renowned anti-allergic characteristics [29][37]. Additionally, CM contains many proteins possessing immunomodulatory properties, including peptidoglycan recognition proteins (PGRPs), Igs, lactoperoxidase (LP), CSA, LF, insulin, and insulin-like proteins [26][27][38]. Among Igs, CM WPs are further reported to contain IgG1 and IgG2, IgG variants that are not present in BM. Apart from CPs and WPs, CM has some milk fat globule membrane proteins, such as milk fat globule-EGF factor 8, adipophilin, lactadherin, fatty acid synthase, and xanthine dehydrogenase. Furthermore, CM has been reported to possess high amounts of N-acetyl-β-glucosaminidase (NAGase), LP, and lysozymes (LZ) [24][39], which confer anti-bacterial, anti-fungal and anti-viral properties.
Figure 1. Representative image delineating various active research endeavors related to CM in food sciences (A). Representative image delineating the beneficial effects of CM and its constituents against various human diseases (B).
Among micronutrients, both water and fat-soluble vitamins, i.e., A, D, E, K, B complex, and C, are present in CM [28][40][41]. CM is also rich in minerals, which are present in the following order of abundance: K > Cl > Ca > P > Na > Mg, Cu, Fe, Zn, etc. [24][27][41][42][43]. It has been reported that the Fe content of CM is approximately 10-fold that in BM and that the K and Cu contents are also higher [27][41]. These elements play important roles in various biological processes, serving either as catalytic or structural components or having specific functions, all indispensable for cellular function [27][41], thereby imparting additional value to CM. In particular, the concentrations of heavy metals in CM are in the harmless range [27][41].

2.2. Pharmacological Properties of CM Bioactive Molecules against Various Pathological Conditions

2.2.1. Molecular Intricacies of Anti-Cancer Effects

Cancer is a very complex disease caused by genetic and/or epigenetic changes that lead to uncontrolled cell growth. According to GLOBOCAN 2020 reports, cancer is the second leading cause of death worldwide, with an estimated 19.3 million cases diagnosed and 10.0 million deaths [44]. The report also predicts that the number of cases will nearly double by 2040 [44]. During tumorigenesis and tumor progression, cancer cells undergo several alterations, including gaining the ability to proliferate, independent of normal growth-promoting or inhibitory signals, invading and migrating to surrounding or distant tissues/sites, promoting angiogenesis, escaping apoptosis, and avoiding replicative senescence and immune responses. It has been posited that these characteristic features are acquired from alterations in cellular signaling pathways that, in normal cells, regulate controlled cell growth.
Traditionally, it was believed that the consumption of CM helped reduce the incidence of cancers; however, molecular evidence for this health benefit is limited [45][46][47]. Various in vitro studies have revealed the inhibitory effects of CM and its constituents against various forms of cancer, apparently through induction of apoptotic pathways [2][12][47][48][49][50][51][52]. In parallel, animal experimental data have also demonstrated the inhibitory potential of CM and its constituents against various forms of cancer [53][54][55]. Interestingly, CM has been shown to interfere with the expression of cancer-related mediators at both gene and protein levels [48]. Furthermore, apart from investigations into the traditional processes, reports have linked autophagic responses with the ameliorative effects of CM against cancer [46]. Autophagy, a process through which the system maintains cellular homeostasis through the removal of dysfunctional organelles and/or dysfunctional/misfolded proteins, has also been studied in relation to particular complications [56]. To this end, Krishnankutty et al. showed that CM exerts anti-proliferative effects on human colorectal cancer cells by orchestration of autophagic responses [46]. An overview of the autophagy process, together with the plausible targets of CM, is illustrated in Figure 2. Interestingly, using the GFP-LC3 puncta assay, Krishnankutty et al. clearly showed an increment in LC3-II formation following treatment with CM. Moreover, a dose-dependent decrease in p62 (sequestosome 1) was observed following treatment with CM. A dose-dependent decrease in the expression of Atg5-12 proteins was observed in two cell lines studied following treatment with CM. Collectively, the group convincingly demonstrated that CM exerted cytotoxicity responses toward human colorectal cancer cells, seemingly through orchestration of autophagic responses, although the identity of the component of CM responsible was not ascertained [46]. Further studies in this direction would be highly instrumental in identifying the active “wonder” component(s) of CM that can selectively kill cancer cells.
Figure 2. Representative image delineating the anti-cancer effect of CM against human colorectal and breast cancer cells through induction of autophagic responses (abbreviations are: LC3: a microtubule- associated protein 1 light chain 3 (LC3-I precursor); PE: phosphatidylethanolamine; LC3-II: Lipidated LC3-I; ATG4 and ATG7, autophagy proteins; ATG5-12, a complex of autophagy proteins; p62: sequestosome 1). Modified from Izadi et al., Journal of Functional food [24].
Furthermore, as a matter of fact, widely used chemotherapeutic drugs have been shown to manifest many negative side effects. Nevertheless, CM has been shown to manifest many beneficial properties without any side effects. Interestingly, these studies suggest that components of CM can modulate signaling cascades and, thus, may represent an alternative to traditional chemotherapeutic drugs and/or act as adjuncts and complements in the management of various disorders, including cancer.

2.2.2. Molecular Intricacies of CM’s Anti-Hypertensive Potential

Hypertension, a high blood pressure (BP) condition, leads to severe health complications and increases the risk of heart disease, stroke, and eventually death. Elevated BP causes long-term detrimental effects on the heart and other organs. In recent years, due to the increasing incidence of hypertensive heart disease, hypertension has emerged as a leading cause of cardiovascular-related morbidity and mortality worldwide [57][58][59]. Several explanations for the mechanism governing hypertension have been proposed [60][61][62]. Accumulating studies have shown that CM and CM-derived proteins and peptides have anti-hypertensive effects [12][22][33][50][63]; generally attributed to the inhibition of angiotensin-converting enzyme (ACE) [33][64][65]. To this end, researchers have recently performed comparative profiling of the bio-macromolecular fractions of CM and BM and ascertained their anti-hypertensive potentials following simulated gastrointestinal digestion [33], and they recent report identified novel anti-hypertensive bioactive peptides from CM protein hydrolysates (CMPHs) and delineated the underlying molecular mechanism of these peptides [10].
The renin–angiotensin system (RAS) is a principal regulatory hormonal system that plays important roles in hypertension [57][58][62][66]. The important effector RAS hormone angiotensin II (Ang II), a vasoconstrictive peptide, has been implicated in regulating the physiological effects of the regulation of BP and is associated with the pathophysiology of hypertension [62][66][67]. Ang II has also been associated with inflammatory responses, endothelial dysfunction, atherosclerosis, and congestive heart failure. Reports have indicated various effects of Ang II, depending on the cell/tissue type under consideration and the duration of exposure (acute versus chronic) [50][62][68]. Ang II is derived from Ang I through the activity of ACE [69][70]. ACE, or kininase II, also plays a key role in the kallikrein-kinin system by cleaving bradykinin to inactive peptides; which, in turn, also have effects on hypertensive responses (Figure 3). Ang II receptors are categorized into two types based on their structure: Ang II type 1 receptor (AT1R) and Ang II type 2 receptor (AT2R), each with a distinctive downstream signaling cascade [69][70]. Signaling through AT1R is envisaged to mediate vasoconstriction, aldosterone secretion, catecholamine release, and cardiac remodeling [71]. However, signaling through AT2R has opposite effects to those mediated by AT1R and has been shown to induce vasodilation [72] and attenuation of cardiac remodeling [73][74].
Figure 3. Representative image delineating the plausible anti-hypertensive effect of CM. At the molecular level, the renin-angiotensin system (RAS) is at the center of the regulation of hypertension. Angiotensin II (Ang II), an important effector RAS hormone, has been implicated in regulating the physiological effects of the regulation of blood pressure and is associated with the pathophysiology of hypertension. Basically, Ang II is derived from Ang I through the activity of Angiotensin Converting Enzyme (ACE). ACE, or kininase II, also plays a key role in the kallikrein-kinin system by cleaving bradykinin to inactive peptides; which, in turn, also affect hypertensive responses (A). Molecular signaling through AT1R is envisaged to mediate aldosterone secretion, ADH secretion, and the arterial vasoconstriction, which ultimately leads to hypertensive response (B). A detailed overview of the molecular signaling mediated by Ang II-AT1R is delineated (C). Interestingly, CM and its constituents have been reported to inhibit ACE.
Ang II has been shown to mediate downstream signaling through the action of G protein- and non-G protein-related signaling mediators [62][66]. However, Ang II also mediates its functions via various mitogen-activated protein kinases, receptor tyrosine kinases and non-receptor tyrosine kinases [66]. In addition, Ang II-AT1R-mediated NAD(P)H oxidase activation, which has been widely implicated in vascular inflammatory and fibrotic responses, has been studied in detail. These signaling pathways regulate normal cellular function and/or disease conditions. A detailed overview of the signal transduction pathways related to Ang II-mediated hypertensive responses is delineated in Figure 3. The plausible target for CM and its constituents has also been highlighted (Figure 3).
Interestingly, the anti-hypertensive potential of CM proteins, PHs and/or bioactive peptides is an important emerging area with promising prospects. It is important to understand how these CM bioactive molecules influence the cellular system at the molecular, cellular, and organelle levels. Further, it is anticipated that the underlying events do not function in isolation but rather influence each other either directly or indirectly, and ultimately affect the underlying responses. Thus, it is equally imperative to understand how these CM bioactive molecules influence these dynamically intertwined responses.、

2.3. Non-Nutritional Components (CM Exosomes)

While the nutritional components of CM have long been recognized and studied in depth, research on the non-nutritional components of CM has recently accelerated [1][3]. Since antiquity, milk, especially CM, has been shown to possess various desirable pharmacological properties [1][15][75][76]. As already mentioned, accumulating evidence has shown that CM bioactive molecules possess various beneficial characteristics, including anti-oxidant, anti-microbial, anti-radical, anti-cancer, anti-hypertension, anti-diabetic, anti-inflammatory, anti-allergic, anti-autism, immunomodulatory effects, etc. [7][15][24][77]. Recent studies have highlighted that these properties can be attributed to the presence of EVs, especially exosomes [1][3]. Milk exosomes have attracted much attention, primarily due to their intrinsic beneficial properties but also because they can serve as nanodrug delivery platforms for therapeutic agents and molecular entities. Further fabrication of exosomes with targeting moieties would allow targeted delivery of drugs/molecular entities to the desired sites.
Exosomes are naturally occurring, nano-sized (20–100 nm) EVs that are released from almost every cell type [78][79]. They are found throughout the body in the extracellular environment and biofluids, including cerebrospinal fluid, serum, saliva, urine, and milk [78][79][80][81][82]. They are mechanistically and functionally diverse from their cellular counterparts and are more heterogeneous, depending on their origin. They are lipid bilayer assemblies containing membrane-bound and internal proteins and a wide range of nucleic acid moieties [79]. It is thought that cellular communication by exosomes occurs through their ability to shuttle cargoes of proteins, circulating DNA, noncoding RNAs, lipid moieties, and metabolites into their surrounding milieu [79][83][84][85]. For example, it has been shown that milk exosomes shuttle genetic material from parents to offspring, thereby playing a role in the regulation of the infant’s development [84].

3. Pharmacological Properties of CM Exosomes

Evidence has shown that exosomes derived from human milk, BM, and CM exhibit antitumor activities [86][87]; however, reports on their anti-diabetic and anti-hypertensive potential are scarce.

3.1. Molecular Intricacies of Their Anti-Cancer Potential

There are many reports on the anti-cancer potential of milk-derived exosomes from bovine sources, and research on CM exosomes is still in its infancy. To the best of researchers' knowledge, Badawy et al. were the first to evaluate the potential effects of CM and its exosomes against breast cancer; they evaluated their chemotherapeutic potential and provided evidence for the underlying mechanism of action [1]. They suggested that the anti-cancer effect of CM exosomes was mediated through the regulation of apoptosis and suppression of angiogenesis, metastasis, and inflammatory responses and that these effects were attributable to miRNA constituents of the exosomes [1]. CM exosomes have also been reported to mitigate oxidative stress and immuno-toxic responses induced by the chemotherapeutic drug cyclophosphamide in an albino rat model [3]. Recently, El-Magd have envisaged the apoptotic, anti-inflammatory, and anti-angiogenesis properties of CM exosomes from colostrum against HepaRG cells [88].

3.2. CM Exosomes as a Natural Biogenic Nano-Delivery Platform for Therapeutics

Milk-derived exosomes have garnered much interest, not only for their intrinsic beneficial properties, but also for their ability to serve as biomimetic nanodrug delivery platforms. The use of milk exosomes as a delivery vehicle for therapeutic drugs and/or siRNA, and the development of exosome-based targeted delivery platforms, constitute an emerging and exciting field.
Gupta et al. were the first to examine the potential of bovine exosomes as a biogenic nano-delivery platform for chemotherapeutic drugs, such as paclitaxel, curcumin, anthocyanidins, celastrol, and siRNA [89][90][91][92][93]. Yassin et al. described a method for isolating CM exosomes using differential ultracentrifugation and provided an in-depth characterization of CM exosomes [94]. They showed that CM exosomes have a truncated 35-kDa protein of the TSG101 marker (compared with the mammalian 43-kDa protein) and an average size of approximately 30 nm. Additionally, using phospholipidomic analysis, PC was found to be the most abundant phospholipid. A detailed analysis of EVs isolated from CM using liquid chromatography with tandem mass spectrometry revealed a variety of protein signatures associated with small EVs, including ADAM10, TSG101, CD3, CD63, CD81, HSP70, and HSP90, which suggests that CM EVs are rich in exosomal proteins. While CM exosomes offer exciting research potential, to leverage their full potential, further standardization and optimization of isolation protocols and improved quality control are important aspects that must not be overlooked. It is equally important to assess the individual components of exosomes responsible for the underlying effects, in parallel with the assessment of their potential toxicity issues.

References

  1. Badawy, A.A.; El-Magd, M.A.; AlSadrah, S.A. Therapeutic Effect of Camel Milk and Its Exosomes on MCF7 Cells In Vitro and In Vivo. Integr. Cance Ther. 2018, 17, 1235–1246.
  2. Habib, H.M.; Ibrahim, W.H.; Schneider-Stock, R.; Hassan, H.M. Camel Milk Lactoferrin Reduces the Proliferation of Colorectal Cancer Cells and Exerts Antioxidant and DNA Damage Inhibitory Activities. Food Chem. 2013, 141, 148–152.
  3. Ibrahim, H.M.; Mohammed-Geba, K.; Tawfic, A.A.; El-Magd, M.A. Camel Milk Exosomes Modulate Cyclophosphamide-Induced Oxidative Stress and Immuno-Toxicity in Rats. Food Funct. 2019, 10, 7523–7532.
  4. Arain, M.A.; Khaskheli, G.B.; Shah, A.H.; Marghazani, I.B.; Barham, G.S.; Shah, Q.A.; Khand, F.M.; Buzdar, J.A.; Soomro, F.; Fazlani, S.A. Nutritional Significance and Promising Therapeutic/Medicinal Application of Camel Milk as a Functional Food in Human and Animals: A Comprehensive Review. Anim. Biotechnol. 2022, 1–18.
  5. Anwar, I.; Khan, F.B.; Maqsood, S.; Ayoub, M.A. Camel Milk Targeting Insulin Receptor—Toward Understanding the Antidiabetic Effects of Camel Milk. Front. Nutr. 2022, 8, 819278.
  6. Khan, F.B.; Anwar, I.; Redwan, E.M.; Palakkott, A.; Ashraf, A.; Kizhakkayil, J.; Iratni, R.; Maqsood, S.; Akli Ayoub, M. Camel and Bovine Milk Lactoferrins Activate Insulin Receptor and Its Related AKT and ERK1/2 Pathways. J. Dairy Sci. 2022, 105, 1848–1861.
  7. Ayoub, M.A.; Palakkott, A.R.; Ashraf, A.; Iratni, R. The Molecular Basis of the Anti-Diabetic Properties of Camel Milk. Diabetes Res. Clin. Pract. 2018, 146, 305–312.
  8. Muthukumaran, M.S.; Mudgil, P.; Baba, W.N.; Ayoub, M.A.; Maqsood, S. A Comprehensive Review on Health Benefits, Nutritional Composition and Processed Products of Camel Milk. Food Rev. Int. 2022, 1–37.
  9. Elagamy, E.I. Effect of Heat Treatment on Camel Milk Proteins with Respect to Antimicrobial Factors: A Comparison with Cows’ and Buffalo Milk Proteins. Food Chem. 2000, 68, 227–232.
  10. Mudgil, P.; Baby, B.; Ngoh, Y.-Y.; Kamal, H.; Vijayan, R.; Gan, C.-Y.; Maqsood, S. Molecular Binding Mechanism and Identification of Novel Anti-Hypertensive and Anti-Inflammatory Bioactive Peptides from Camel Milk Protein Hydrolysates. LWT 2019, 112, 108193.
  11. Agrawal, R.P.; Beniwal, R.; Kochar, D.K.; Tuteja, F.C.; Ghorui, S.K.; Sahani, M.S.; Sharma, S. Camel Milk as an Adjunct to Insulin Therapy Improves Long-Term Glycemic Control and Reduction in Doses of Insulin in Patients with Type-1 Diabetes A 1 Year Randomized Controlled Trial. Diabetes Res Clin Pract. 2005, 68, 176–177.
  12. Ayyash, M.; Al-Dhaheri, A.S.; Al Mahadin, S.; Kizhakkayil, J.; Abushelaibi, A. In Vitro Investigation of Anticancer, Antihypertensive, Antidiabetic, and Antioxidant Activities of Camel Milk Fermented with Camel Milk Probiotic: A Comparative Study with Fermented Bovine Milk. J. Dairy Sci. 2018, 101, 900–911.
  13. He, J.; Guo, K.; Chen, Q.; Wang, Y. Jirimutu Camel Milk Modulates the Gut Microbiota and Has Anti-Inflammatory Effects in a Mouse Model of Colitis. J. Dairy Sci. 2022, 105, 3782–3793.
  14. Ashraf, A.; Mudgil, P.; Palakkott, A.; Iratni, R.; Gan, C.-Y.; Maqsood, S.; Ayoub, M.A. Molecular Basis of the Anti-Diabetic Properties of Camel Milk through Profiling of Its Bioactive Peptides on Dipeptidyl Peptidase IV (DPP-IV) and Insulin Receptor Activity. J. Dairy Sci. 2021, 104, 61–77.
  15. Abdulrahman, A.O.; Ismael, M.A.; Al-Hosaini, K.; Rame, C.; Al-Senaidy, A.M.; Dupont, J.; Ayoub, M.A. Differential Effects of Camel Milk on Insulin Receptor Signaling–Toward Understanding the Insulin-Like Properties of Camel Milk. Front. Endocrinol. 2016, 7, 4.
  16. Agrawal, R.P.; Budania, S.; Sharma, P.; Gupta, R.; Kochar, D.K.; Panwar, R.B.; Sahani, M.S. Zero Prevalence of Diabetes in Camel Milk Consuming Raica Community of North-West Rajasthan, India. Diabetes Res. Clin. Pract. 2007, 76, 290–296.
  17. Agrawal, R.P.; Saran, S.; Sharma, P.; Gupta, R.P.; Kochar, D.K.; Sahani, M.S. Effect of Camel Milk on Residual Beta-Cell Function in Recent Onset Type 1 Diabetes. Diabetes Res. Clin. Pract. 2007, 77, 494–495.
  18. Agrawal, R.P.; Sharma, P.; Gafoorunissa, S.J.; Ibrahim, S.A.; Shah, B.; Shukla, D.K.; Kaur, T. Effect of Camel Milk on Glucose Metabolism in Adults with Normal Glucose Tolerance and Type 2 Diabetes in Raica Community: A Crossover Study. Acta Biomed. 2011, 82, 181–186.
  19. Abou-Soliman, N.H.I.; Awad, S.; Desouky, M.M. Effect of Digestive Enzymes on the Activity of Camel-Milk Insulin. Int. J. Dairy Technol. 2020, 73, 341–344.
  20. Vaisman, N.; Reuven, Y.; Uzi, M.; Georgi, G.; Boehm, G. Camel’s Milk and Gastric Emptying. Clin. Nutr. 2006, 25, 622–625.
  21. Malik, A.; Al-Senaidy, A.; Skrzypczak-Jankun, E.; Jankun, J. A Study of the Anti-Diabetic Agents of Camel Milk. Int. J. Mol. Med. 2012, 30, 585–592.
  22. Mati, A.; Senoussi-Ghezali, C.; Zennia, S.S.A.; Almi-Sebbane, D.; El-Hatmi, H.; Girardet, J.-M. Dromedary Camel Milk Proteins, a Source of Peptides Having Biological Activities—A Review. Int. Dairy J. 2017, 73, 25.
  23. Ali Redha, A.; Valizadenia, H.; Siddiqui, S.A.; Maqsood, S. A State-of-Art Review on Camel Milk Proteins as an Emerging Source of Bioactive Peptides with Diverse Nutraceutical Properties. Food Chem. 2022, 373, 131444.
  24. Izadi, A.; Khedmat, L.; Mojtahedi, S.Y. Nutritional and Therapeutic Perspectives of Camel Milk and Its Protein Hydrolysates: A Review on Versatile Biofunctional Properties. J. Funct. Foods 2019, 60, 103441.
  25. He, J.; Xiao, Y.; Orgoldol, K.; Ming, L.; Yi, L.; Ji, R. Effects of Geographic Region on the Composition of Bactrian Camel Milk in Mongolia. Animals 2019, 9, 890.
  26. Konuspayeva, G.; Faye, B.; Loiseau, G. The Composition of Camel Milk: A Meta-Analysis of the Literature Data. J. Food Compos. Anal. 2009, 22, 95–101.
  27. Al haj, O.A.; Al Kanhal, H.A. Compositional, Technological and Nutritional Aspects of Dromedary Camel Milk. Int. Dairy J. 2010, 20, 811–821.
  28. Farah, Z.; Rettenmaier, R.; Atkins, D. Vitamin Content of Camel Milk. Int. J. Vitam. Nutr. Res. 1992, 62, 30–33.
  29. Khalesi, M.; Salami, M.; Moslehishad, M.; Winterburn, J.; Moosavi-Movahedi, A.A. Biomolecular Content of Camel Milk: A Traditional Superfood towards Future Healthcare Industry. Trends Food Sci. Technol. 2017, 62, 49–58.
  30. Meena, S.; Rajput, Y.S.; Sharma, R. Comparative Fat Digestibility of Goat, Camel, Cow and Buffalo Milk. Int. Dairy J. 2014, 35, 153–156.
  31. Shuiep, E.T.S.; Giambra, I.J.; El-Zubeir, I.E.Y.M.; Erhardt, G. Biochemical and Molecular Characterization of Polymorphisms of As1-Casein in Sudanese Camel (Camelus Dromedarius) Milk. Int. Dairy J. 2013, 28, 88–93.
  32. El-Agamy, E.I. Bioactive Components in Camel Milk. Bioact. Compon. Milk Dairy Prod. 2009, 107, 159–192.
  33. Maqsood, S.; Al-Dowaila, A.; Mudgil, P.; Kamal, H.; Jobe, B.; Hassan, H.M. Comparative Characterization of Protein and Lipid Fractions from Camel and Cow Milk, Their Functionality, Antioxidant and Antihypertensive Properties upon Simulated Gastro-Intestinal Digestion. Food Chem. 2019, 279, 328–338.
  34. Hailu, Y.; Hansen, E.B.; Seifu, E.; Eshetu, M.; Ipsen, R.; Kappeler, S. Functional and Technological Properties of Camel Milk Proteins: A Review. J. Dairy Res. 2016, 83, 422–429.
  35. Khaskheli, M.; Arain, M.A.; Chaudhry, S.; Soomro, A.H.; Qureshi, T.A. Physico-Chemical Quality of Camel Milk. J. Agric. Soc. Sci. 2005, 2, 164–166.
  36. Mehaia, M.A.; Hablas, M.A.; Abdel-Rahman, K.M.; El-Mougy, S.A. Milk Composition of Majaheim, Wadah and Hamra Camels in Saudi Arabia. Food Chem. 1995, 52, 115–122.
  37. Omar, A.; Harbourne, N.; Oruna-Concha, M.J. Quantification of Major Camel Milk Proteins by Capillary Electrophoresis. Int. Dairy J. 2016, 58, 31–35.
  38. Felfoul, I.; Jardin, J.; Gaucheron, F.; Attia, H.; Ayadi, M.A. Proteomic Profiling of Camel and Cow Milk Proteins under Heat Treatment. Food Chem. 2017, 216, 161–169.
  39. Kappeler, S.R.; Heuberger, C.; Farah, Z.; Puhan, Z. Expression of the Peptidoglycan Recognition Protein, PGRP, in the Lactating Mammary Gland. J. Dairy Sci. 2004, 87, 2660–2668.
  40. Stahl, T.; Sallmann, H.-P.; Duehlmeier, R.; Wernery, U. Selected Vitamins and Fatty Acid Patterns in Dromedary Milk and Colostrum. J. Camel Pract. Res. 2006, 13, 53–57.
  41. Alhaj, O.A.; Altooq, N.J.; Alenezi, A.F.; Janahi, A.I.; Janahi, M.I.; Humood, A.M.; AlRasheed, M.M.; Bragazzi, N.L.; Jahrami, H.A.; Faye, B. Camel Milk Composition by Breed, Season, Publication Year, and Country: A Global Systematic Review, Meta-Analysis, and Meta-Regression. Compr. Rev. Food Sci. Food Saf. 2022, 21, 2520–2559.
  42. Alavi, F.; Salami, M.; Emam-Djomeh, Z.; Mohammadian, M. Nutraceutical Properties of Camel Milk. In Nutrients in Dairy and Their Implications for Health and Disease; Elsevier: Amsterdam, The Netherlands, 2017; pp. 451–468. ISBN 978-0-12-809762-5.
  43. Yaqoob, M.; Nawaz, H. Potential of Pakistani Camel for Dairy and Other Uses. Anim. Sci. J. 2007, 78, 467–475.
  44. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249.
  45. Korashy, H.M.; El Gendy, M.A.M.; Alhaider, A.A.; El-Kadi, A.O. Camel Milk Modulates the Expression of Aryl Hydrocarbon Receptor-Regulated Genes, Cyp1a1, Nqo1, and Gsta1, in Murine Hepatoma Hepa 1c1c7 Cells. J. Biomed. Biotechnol. 2012, 2012, e782642.
  46. Krishnankutty, R.; Iskandarani, A.; Therachiyil, L.; Uddin, S.; Azizi, F.; Kulinski, M.; Bhat, A.A.; Mohammad, R.M. Anticancer Activity of Camel Milk via Induction of Autophagic Death in Human Colorectal and Breast Cancer Cells. Asian Pac. J. Cancer Prev. 2018, 19, 3501–3509.
  47. Shariatikia, M.; Behbahani, M.; Mohabatkar, H. Anticancer Activity of Cow, Sheep, Goat, Mare, Donkey and Camel Milks and Their Caseins and Whey Proteins and in Silico Comparison of the Caseins. Mol. Biol. Res. Commun. 2017, 6, 57–64.
  48. Korashy, H.M.; Maayah, Z.H.; Abd-Allah, A.R.; El-Kadi, A.O.S.; Alhaider, A.A. Camel Milk Triggers Apoptotic Signaling Pathways in Human Hepatoma HepG2 and Breast Cancer MCF7 Cell Lines through Transcriptional Mechanism. J. Biomed. Biotechnol. 2012, 2012, 593195.
  49. Hasson, S.S.A.A.; Al-Busaidi, J.Z.; Al-Qarni, Z.A.M.; Rajapakse, S.; Al-Bahlani, S.; Idris, M.A.; Sallam, T.A. In Vitro Apoptosis Triggering in the BT-474 Human Breast Cancer Cell Line by Lyophilised Camel’s Milk. Asian Pac. J. Cancer Prev. 2015, 16, 6651–6661.
  50. Ayyash, M.; Al-Nuaimi, A.K.; Al-Mahadin, S.; Liu, S.-Q. In Vitro Investigation of Anticancer and ACE-Inhibiting Activity, α-Amylase and α-Glucosidase Inhibition, and Antioxidant Activity of Camel Milk Fermented with Camel Milk Probiotic: A Comparative Study with Fermented Bovine Milk. Food Chem. 2018, 239, 588–597.
  51. Abdallah, L.A.; Sawafta, A.M.; Ali, S.A.B.; Baradia, H.A. Cytotoxic Potential of Camel Whey and Milk on Cervix Cancer (HeLa) Cell Line. Asian J. Med. Biol. Res. 2019, 5, 231–236.
  52. Yang, J.; Dou, Z.; Peng, X.; Wang, H.; Shen, T.; Liu, J.; Li, G.; Gao, Y. Transcriptomics and Proteomics Analyses of Anti-Cancer Mechanisms of TR35-An Active Fraction from Xinjiang Bactrian Camel Milk in Esophageal Carcinoma Cell. Clin. Nutr. 2019, 38, 2349–2359.
  53. El Miniawy, H.M.F.; Ahmed, K.A.; Mansour, S.A.; Khattab, M.M.S. In Vivo Antitumour Potential of Camel’s Milk against Hepatocellular Carcinoma in Rats and Its Improvement of Cisplatin Renal Side Effects. Pharm. Biol. 2017, 55, 1513–1520.
  54. Al-Omari, M.M.; Razan, B.; Al-Ghariebeh, A.A.A.A.; Zoubi, H.A.-; Al-Qaoud, K.M. Camel Milk Whey Inhibits Inflammatory Colorectal Cancer Development Via Down Regulation of Pro-Inflammatory Cytokines in Induced AOM/DSS Mouse Model. Emir. J. Food Agric. 2019, 31, 256–262.
  55. Alhaider, A.A.; Abdel Gader, A.G.M.; Almeshaal, N.; Saraswati, S. Camel Milk Inhibits Inflammatory Angiogenesis via Downregulation of Proangiogenic and Proinflammatory Cytokines in Mice. APMIS 2014, 122, 599–607.
  56. Galluzzi, L.; Baehrecke, E.H.; Ballabio, A.; Boya, P.; Bravo-San Pedro, J.M.; Cecconi, F.; Choi, A.M.; Chu, C.T.; Codogno, P.; Colombo, M.I.; et al. Molecular Definitions of Autophagy and Related Processes. EMBO J. 2017, 36, 1811–1836.
  57. Chiang, J.-T.; Badrealam, K.F.; Shibu, M.A.; Cheng, S.-F.; Shen, C.-Y.; Chang, C.-F.; Lin, Y.-M.; Viswanadha, V.P.; Liao, S.-C.; Huang, C.-Y. Anti-Apoptosis and Anti-Fibrosis Effects of Eriobotrya Japonica in Spontaneously Hypertensive Rat Hearts. Int. J. Mol. Sci. 2018, 19, 1638.
  58. Chiang, J.-T.; Badrealam, K.F.; Shibu, M.A.; Kuo, C.-H.; Huang, C.-Y.; Chen, B.-C.; Lin, Y.-M.; Viswanadha, V.P.; Kuo, W.-W.; Huang, C.-Y. Eriobotrya Japonica Ameliorates Cardiac Hypertrophy in H9c2 Cardiomyoblast and in Spontaneously Hypertensive Rats. Environ. Toxicol. 2018, 33, 1113–1122.
  59. Lin, Y.-M.; Badrealam, K.F.; Kuo, W.-W.; Lai, P.F.; Shao-Tsu Chen, W.; Hsuan Day, C.; Ho, T.-J.; Viswanadha, V.P.; Shibu, M.A.; Huang, C.-Y. Nerolidol Improves Cardiac Function in Spontaneously Hypertensive Rats by Inhibiting Cardiac Inflammation and Remodelling Associated TLR4/ NF-ΚB Signalling Cascade. Food Chem. Toxicol. 2021, 147, 111837.
  60. Garbers, D.L.; Dubois, S.K. The Molecular Basis of Hypertension. Annu. Rev. Biochem. 1999, 68, 127–155.
  61. Te Riet, L.; van Esch, J.H.M.; Roks, A.J.M.; van den Meiracker, A.H.; Danser, A.H.J. Hypertension: Renin-Angiotensin-Aldosterone System Alterations. Circ. Res. 2015, 116, 960–975.
  62. Mehta, P.K.; Griendling, K.K. Angiotensin II Cell Signaling: Physiological and Pathological Effects in the Cardiovascular System. Am. J. Physiol.-Cell Physiol. 2007, 292, C82–C97.
  63. Yahya, M.A.; Alhaj, O.A.; Al-Khalifah, A.S. Antihypertensive Effect of Fermented Skim Camel (Camelus Dromedarius) Milk on Spontaneously Hypertensive Rats. Nutr. Hosp. 2017, 34, 416–421.
  64. Rahimi, M.; Ghaffari, S.M.; Salami, M.; Mousavy, S.J.; Niasari-Naslaji, A.; Jahanbani, R.; Yousefinejad, S.; Khalesi, M.; Moosavi-Movahedi, A.A. ACE-Inhibitory and Radical Scavenging Activities of Bioactive Peptides Obtained from Camel Milk Casein Hydrolysis with Proteinase K. Dairy Sci. Technol. 2016, 96, 489–499.
  65. Tagliazucchi, D.; Shamsia, S.; Conte, A. Release of Angiotensin Converting Enzyme-Inhibitory Peptides during in Vitro Gastro-Intestinal Digestion of Camel Milk. Int. Dairy J. 2016, 56, 119–128.
  66. Forrester, S.J.; Booz, G.W.; Sigmund, C.D.; Coffman, T.M.; Kawai, T.; Rizzo, V.; Scalia, R.; Eguchi, S. Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology. Physiol. Rev. 2018, 98, 1627–1738.
  67. Ogihara, T.; Higashimori, K.; Masuo, K.; Mikami, H. Pilot Study of a New Angiotensin II Receptor Antagonist, TCV-116: Effects of a Single Oral Dose on Blood Pressure in Patients with Essential Hypertension. Clin. Ther. 1993, 15, 684–691.
  68. Ji, Y.; Liu, J.; Wang, Z.; Liu, N. Angiotensin II Induces Inflammatory Response Partly via Toll-like Receptor 4-Dependent Signaling Pathway in Vascular Smooth Muscle Cells. Cell Physiol. Biochem. 2009, 23, 265–276.
  69. Kang, P.M.; Landau, A.J.; Eberhardt, R.T.; Frishman, W.H. Angiotensin II Receptor Antagonists: A New Approach to Blockade of the Renin-Angiotensin System. Am. Heart J. 1994, 127, 1388–1401.
  70. Timmermans, P.B.; Wong, P.C.; Chiu, A.T.; Herblin, W.F.; Benfield, P.; Carini, D.J.; Lee, R.J.; Wexler, R.R.; Saye, J.A.; Smith, R.D. Angiotensin II Receptors and Angiotensin II Receptor Antagonists. Pharm. Rev. 1993, 45, 205–251.
  71. Matsubara, H. Pathophysiological Role of Angiotensin II Type 2 Receptor in Cardiovascular and Renal Diseases. Circ. Res. 1998, 83, 1182–1191.
  72. Carey, R.M.; Wang, Z.Q.; Siragy, H.M. Role of the Angiotensin Type 2 Receptor in the Regulation of Blood Pressure and Renal Function. Hypertension 2000, 35, 155–163.
  73. Oishi, Y.; Ozono, R.; Yano, Y.; Teranishi, Y.; Akishita, M.; Horiuchi, M.; Oshima, T.; Kambe, M. Cardioprotective Role of AT2 Receptor in Postinfarction Left Ventricular Remodeling. Hypertension 2003, 41, 814–818.
  74. Tsutsumi, Y.; Matsubara, H.; Ohkubo, N.; Mori, Y.; Nozawa, Y.; Murasawa, S.; Kijima, K.; Maruyama, K.; Masaki, H.; Moriguchi, Y.; et al. Angiotensin II Type 2 Receptor Is Upregulated in Human Heart With Interstitial Fibrosis, and Cardiac Fibroblasts Are the Major Cell Type for Its Expression. Circ. Res. 1998, 83, 1035–1046.
  75. Abrhaley, A.; Leta, S. Medicinal Value of Camel Milk and Meat. J. Appl. Anim. Res. 2018, 46, 552–558.
  76. Agrawal, R.P.; Dogra, R.; Mohta, N.; Tiwari, R.; Singhal, S.; Sultania, S. Beneficial Effect of Camel Milk in Diabetic Nephropathy. Acta Biomed. 2009, 80, 131–134.
  77. Mudgil, P.; Kamal, H.; Yuen, G.C.; Maqsood, S. Characterization and Identification of Novel Antidiabetic and Anti-Obesity Peptides from Camel Milk Protein Hydrolysates. Food Chem. 2018, 259, 46–54.
  78. Chen, T.; Xi, Q.-Y.; Ye, R.-S.; Cheng, X.; Qi, Q.-E.; Wang, S.-B.; Shu, G.; Wang, L.-N.; Zhu, X.-T.; Jiang, Q.-Y.; et al. Exploration of MicroRNAs in Porcine Milk Exosomes. BMC Genom. 2014, 15, 100.
  79. Kalluri, R.; LeBleu, V.S. The Biology, Function, and Biomedical Applications of Exosomes. Science 2020, 367, eaau6977.
  80. Ogawa, Y.; Kanai-Azuma, M.; Akimoto, Y.; Kawakami, H.; Yanoshita, R. Exosome-like Vesicles with Dipeptidyl Peptidase IV in Human Saliva. Biol. Pharm. Bull. 2008, 31, 1059–1062.
  81. Admyre, C.; Johansson, S.M.; Qazi, K.R.; Filén, J.-J.; Lahesmaa, R.; Norman, M.; Neve, E.P.A.; Scheynius, A.; Gabrielsson, S. Exosomes with Immune Modulatory Features Are Present in Human Breast Milk. J. Immunol. 2007, 179, 1969–1978.
  82. Hata, T.; Murakami, K.; Nakatani, H.; Yamamoto, Y.; Matsuda, T.; Aoki, N. Isolation of Bovine Milk-Derived Microvesicles Carrying MRNAs and MicroRNAs. Biochem. Biophys. Res. Commun. 2010, 396, 528–533.
  83. Huang-Doran, I.; Zhang, C.-Y.; Vidal-Puig, A. Extracellular Vesicles: Novel Mediators of Cell Communication In Metabolic Disease. Trends Endocrinol. Metab. 2017, 28, 3–18.
  84. Zempleni, J.; Aguilar-Lozano, A.; Sadri, M.; Sukreet, S.; Manca, S.; Wu, D.; Zhou, F.; Mutai, E. Biological Activities of Extracellular Vesicles and Their Cargos from Bovine and Human Milk in Humans and Implications for Infants. J. Nutr. 2017, 147, 3–10.
  85. Valadi, H.; Ekström, K.; Bossios, A.; Sjöstrand, M.; Lee, J.J.; Lötvall, J.O. Exosome-Mediated Transfer of MRNAs and MicroRNAs Is a Novel Mechanism of Genetic Exchange between Cells. Nat. Cell Biol. 2007, 9, 654–659.
  86. Kim, K.-U.; Kim, W.-H.; Jeong, C.H.; Yi, D.Y.; Min, H. More than Nutrition: Therapeutic Potential of Breast Milk-Derived Exosomes in Cancer. Int. J. Mol. Sci. 2020, 21, 7327.
  87. Reif, S.; Elbaum Shiff, Y.; Golan-Gerstl, R. Milk-Derived Exosomes (MDEs) Have a Different Biological Effect on Normal Fetal Colon Epithelial Cells Compared to Colon Tumor Cells in a MiRNA-Dependent Manner. J. Transl. Med. 2019, 17, 325.
  88. El-kattawy, A.M.; Algezawy, O.; Alfaifi, M.Y.; Noseer, E.A.; Hawsawi, Y.M.; Alzahrani, O.R.; Algarni, A.; Kahilo, K.A.; El-Magd, M.A. Therapeutic Potential of Camel Milk Exosomes against HepaRG Cells with Potent Apoptotic, Anti-Inflammatory, and Anti-Angiogenesis Effects for Colostrum Exosomes. Biomed. Pharmacother. 2021, 143, 112220.
  89. Agrawal, A.K.; Aqil, F.; Jeyabalan, J.; Spencer, W.A.; Beck, J.; Gachuki, B.W.; Alhakeem, S.S.; Oben, K.; Munagala, R.; Bondada, S.; et al. Milk-Derived Exosomes for Oral Delivery of Paclitaxel. Nanomed. Nanotechnol. Biol. Med. 2017, 13, 1627–1636.
  90. Aqil, F.; Munagala, R.; Jeyabalan, J.; Agrawal, A.K.; Gupta, R. Exosomes for the Enhanced Tissue Bioavailability and Efficacy of Curcumin. AAPS J. 2017, 19, 1691–1702.
  91. Aqil, F.; Munagala, R.; Jeyabalan, J.; Agrawal, A.K.; Kyakulaga, A.-H.; Wilcher, S.A.; Gupta, R.C. Milk Exosomes-Natural Nanoparticles for SiRNA Delivery. Cancer Lett. 2019, 449, 186–195.
  92. Kandimalla, R.; Aqil, F.; Tyagi, N.; Gupta, R. Milk Exosomes: A Biogenic Nanocarrier for Small Molecules and Macromolecules to Combat Cancer. Am. J. Reprod. Immunol. 2021, 85, e13349.
  93. Munagala, R.; Aqil, F.; Jeyabalan, J.; Gupta, R.C. Bovine Milk-Derived Exosomes for Drug Delivery. Cancer Lett. 2016, 371, 48–61.
  94. Yassin, A.M.; Hamid, M.I.A.; Farid, O.A.; Amer, H.; Warda, M. Dromedary Milk Exosomes as Mammary Transcriptome Nano-Vehicle: Their Isolation, Vesicular and Phospholipidomic Characterizations. J. Adv. Res. 2016, 7, 749–756.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Infectious Diseases
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Farheen Badrealam Khan
,
Mohammad Azam Ansari
,
Shahab Uddin
,
Abdul Rasheed Palakott
,
Irfa Anwar
,
Ahmad Almatroudi
,
Mohammad N. Alomary
,
Faris Alrumaihi
,
Faris F. Aba Alkhayl
,
Saad Alghamdi
,
Khalid Muhammad
,
Chih-Yang Huang
,
Jayasimha Rayalu Daddam
,
Haroon Khan
,
Sajid Maqsood
,
Mohammed Akli Ayoub
View Times: 860
Revisions: 2 times (View History)
Update Date: 14 Jul 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Academic Video Service
    Feedback